{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:09:47Z","timestamp":1773306587842,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.jacl.2010.02.002","type":"journal-article","created":{"date-parts":[[2010,2,13]],"date-time":"2010-02-13T04:40:36Z","timestamp":1266036036000},"page":"105-112.e1","source":"Crossref","is-referenced-by-count":24,"title":["Safety of extended-release niacin\/laropiprant in patients with dyslipidemia"],"prefix":"10.1016","volume":"4","author":[{"given":"James","family":"McKenney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold","family":"Bays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Koren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie\u00a0M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yale","family":"Mitchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigaile","family":"Betteridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Kuznetsova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Sapre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine McCrary","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darbie","family":"Maccubbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6 Suppl","key":"10.1016\/j.jacl.2010.02.002_bib1","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1067\/mhj.2002.130301","article-title":"High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease","volume":"144","author":"Gotto","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2010.02.002_bib2","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1161\/hc4401.098467","article-title":"Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins\u2014an idea whose time for testing is coming, Part I","volume":"104","author":"Shah","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2010.02.002_bib3","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2010.02.002_bib4","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.221.8.918","article-title":"The coronary drug project","volume":"221","author":"Anon","year":"1972","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2010.02.002_bib5","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2010.02.002_bib6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1749-6632.1994.tb17337.x","article-title":"Types of change in coronary stenosis severity and their relative importance in overall progression and regression in coronary disease. Observations from the FATS trial. Familial Atherosclerosis Treatment study","volume":"748","author":"Brown","year":"1995","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.jacl.2010.02.002_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0002-9149(97)00303-2","article-title":"Moderate dose, 3-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg\/dl in patients with hyperlipidemia and coronary artery disease","volume":"80","author":"Brown","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2010.02.002_bib8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.231.4.360","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"The Coronary Drug Project Research Group","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2010.02.002_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2010.02.002_bib10","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am\u00a0J\u00a0Cardiol"},{"key":"10.1016\/j.jacl.2010.02.002_bib11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2010.02.002_bib12","first-page":"229","article-title":"Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice","volume":"62","author":"Birjmohun","year":"2004","journal-title":"Neth J Med"},{"key":"10.1016\/j.jacl.2010.02.002_bib13","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinte.154.14.1586","article-title":"Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial","volume":"154","author":"Illingworth","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2010.02.002_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-3-4","article-title":"The safety of over-the-counter niacin. A randomized placebo-controlled trial","volume":"3","author":"Mills","year":"2003","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.jacl.2010.02.002_bib15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.amjcard.2006.08.063","article-title":"Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice","volume":"99","author":"Kamal-Bahl","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2010.02.002_bib16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1185\/03007990802083408","article-title":"Dosage, titration, and gaps in treatment with extended release niacin in clinical practice","volume":"24","author":"Kamal-Bahl","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2010.02.002_bib17","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2010.02.002_bib18","first-page":"114","article-title":"Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man","volume":"57","author":"Kaijser","year":"1979","journal-title":"Med Biol"},{"key":"10.1016\/j.jacl.2010.02.002_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0163-7827(93)90017-Q","article-title":"Prostanoid receptors and their biological actions","volume":"32","author":"Negishi","year":"1993","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.jacl.2010.02.002_bib20","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1021\/jm0603668","article-title":"Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic Acid (MK-0524)","volume":"50","author":"Sturino","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.jacl.2010.02.002_bib21","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","article-title":"Lipid-modifying efficacy and tolerability of extended-release niacin\/laropiprant in patients with primary hypercholesteroaemia or mixed dyslipidaemia","volume":"62","author":"Maccubbin","year":"2008","journal-title":"Int J\u00a0Clin Pract"},{"key":"10.1016\/j.jacl.2010.02.002_bib22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2010.02.002_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00228-006-0211-2","article-title":"The effect of MK-0524, a prostaglandin D2 receptor antagonist, on prostaglandin D2-induced nasal airway obstruction in healthy volunteers","volume":"63","author":"Van Hecken","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jacl.2010.02.002_bib24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.clpt.6100345","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist","volume":"83","author":"Lai","year":"2008","journal-title":"Clin Pharacol Ther"},{"key":"10.1016\/j.jacl.2010.02.002_bib25","first-page":"90","article-title":"Efficacy and safety profile of co-administered ER niacin\/laropiprant and simvastatin in dyslipidaemia","volume":"16","author":"Gleim","year":"2009","journal-title":"Br J Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2010.02.002_bib26","first-page":"A324","article-title":"Flushing profile of extended release niacin\/laropiprant versus gradually titrated Niaspan\u2122 in patients with dyslipidemia","volume":"51","author":"Koren","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2010.02.002_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0002-9149(97)01016-3","article-title":"Effects of crystalline nicotinic acid-induced hepatic dysfunction of serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase","volume":"81","author":"Tat\u00f2","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2010.02.002_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0002-9343(92)90018-7","article-title":"Hepatic toxicity of unmodified and time-release preparations of niacin","volume":"92","author":"Rader","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2010.02.002_bib29","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dysplipidemia associated with type 2 diabetes\u2014results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2010.02.002_bib30","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2010.02.002_bib31","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287410000498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287410000498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T19:32:29Z","timestamp":1558812749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287410000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1933287410000498"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2010.02.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}